Curevo: Funding, Investors & Team (Sep 2026)
In order to expedite the creation of safe and highly efficient vaccines from the bench through clinical testing, Curevo will integrate the best aspects of protein science and adjuvant technology. Curevo will concentrate on diseases that can be prevented by vaccination that are widespread in both the Asian and US markets but for which there are currently no vaccine products available. By collaborating with the Seattle, Washington-based Infectious Disease Research Institute, the South Korean Mogam Institute for Biomedical Research, and GC Pharma, Cuervo hopes to quickly advance novel new vaccine candidates from the research lab to the clinic.
Curevo has raised $26.0M across 1 funding round on record, the most recent a Series A of $26.0M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Curevo Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Curevo Funding Rounds
Curevo Founders and Leadership Team
Contact details for the Curevo team: 1 of 1 has an email address on file.
Start 14-day free trial →Curevo Funding Compared to Other Biotechnology Startups
Curevo's latest round of $26.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Curevo in Biotechnology and Bothell
Companies Similar to Curevo
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Curevo Funding FAQs
What does Curevo do?
In order to expedite the creation of safe and highly efficient vaccines from the bench through clinical testing, Curevo will integrate the best aspects of protein science and adjuvant technology. Curevo will concentrate on diseases that can be prevented by vaccination that are widespread in both the Asian and US markets but for which there are currently no vaccine products available. By collaborating with the Seattle, Washington-based Infectious Disease Research Institute, the South Korean Mogam Institute for Biomedical Research, and GC Pharma, Cuervo hopes to quickly advance novel new vaccine candidates from the research lab to the clinic.
How much funding has Curevo raised?
Curevo has raised $26.0M across 1 round on record. The most recent is a Series A of $26.0M announced in Nov 2022.
When did Curevo last raise funding?
Curevo's most recent funding round on record is a Series A of $26.0M, announced in Nov 2022.
Who is the CEO of Curevo?
George Simeon is listed as CEO at Curevo.
Where is Curevo headquartered?
Curevo is based in Bothell, Washington, United States.
How many employees does Curevo have?
Curevo is in the 11-50 employee band.
How does Curevo's funding compare to other Biotechnology startups?
Curevo's latest round of $26.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Curevo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Curevo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.